(EMAILWIRE.COM, June 27, 2006 ) HAIFA, Israel —- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, expects their PLX line of products to eventually eliminate the current bone marrow transplant search and match process. Pluristem’s PLX product line is positioned as a potential cure to currently incurable blood cancer situations. Once fully developed and commercialized, it will enable umbilical cord blood to become an alternative to traditional bone marrow transplantation.

Pluristem’s three-dimensional patented technology enables the effective use of the rare stem cells found in umbilical cord blood. PLX mimics the micro environment of bone marrow in a "green" process without the use of exogenous chemicals. By improving the engraftment of umbilical cord blood, it could solve the shortfall of matched bone marrow donors.

About Pluristem

Pluristem Life Systems, Inc. is a cell therapy company dedicated to the commercialization of stem cell therapy products for the treatment of severe blood disorders. Pluristem is discovering and developing call-based therapeutics utilizing adult stem cells expanded in a proprietary bio-reactor that mimics different naturally-occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation to treat blood cancer and other blood disorders.


Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include statements that it expects its PLX line of products to eventually eliminate the current bone marrow transplant search and match process; that Pluristem’s PLX product line is positioned as a potential cure to currently incurable blood cancer situations; that once fully developed and commercialized, it will enable umbilical cord blood to become an alternative to traditional bone marrow transplantation; that it could solve the shortfall of matched bone marrow donors; and that Pluristem is discovering and developing cell-based therapeutics. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company’s latest 10-KSB filed with the SEC.

For more information visit our website at www.pluristem.com

Investor Contact
Yossi Keret
Pluristem Life Systems, Inc.
Haifa, Israel
011-972-54-800-8404
Yossi@pluristem.com

Media Contact
Jerry Jennings
Emerson Gerard Associates, Inc.
West Palm Beach, FL
561-881-7318
mediareply@emersongerard.com

Contact Information:
Pluristem Life Systems
Gerard Jennings
Tel:
Email us